AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

InMed Pharmaceuticals Inc... (INM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.52

-0.27 (-7.12%)

At close: Jan 29, 2025, 3:58 PM

3.52

0.04%

After-hours Jan 29, 2025, 03:59 PM EST

undefined% (undefined)

Bid	3.4
Market Cap	2.55M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	230.4
PE Ratio (ttm)	0.02
Forward PE	n/a
Analyst	n/a

Ask	3.73
Volume	77,217
Avg. Volume (20D)	485,810
Open	3.73
Previous Close	3.79
Day's Range	3.38 - 3.80
52-Week Range	2.42 - 15.70
Beta	undefined

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it en...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 5, 2014

Employees 13

Stock Exchange NASDAQ

Ticker Symbol INM

Website https://www.inmedpharma.com

Why Price Moved

1 week ago

+2.02%

InMed Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription

2 months ago

-15.75%

InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

News

1 week ago · newsfilecorp.com

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, i...

1 week ago · newsfilecorp.com

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile sho...

1 month ago · newsfilecorp.com

InMed Announces Results of 2024 Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

1 month ago · newsfilecorp.com

InMed Enters Into Standby Equity Purchase Agreement

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

2 months ago · newsfilecorp.com

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic...

2 months ago · newsfilecorp.com

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...

2 months ago · newsfilecorp.com

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...

2 months ago · newsfilecorp.com

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...